Passage Bio, Inc. (PASG)
Stock Price:
$15.81 USD
-0.78 (-4.70%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
719.14M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
45.49M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$15.81 |
| Previous Close |
$16.59 |
| Change ($) |
-0.78 |
| Change (%) |
-4.70% |
| Day's Open |
16.79 |
| Day's Range |
15.75 - 17.07 |
| Day's Volume |
338,148 |
| 52-Week Range |
8.09 - 38.23 |
More Stats
| Market Cap |
719.14M |
| Enterprise Value |
365.72M |
| Earnings Date (est) |
May 17, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.49M |
| Float |
21.98M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.39M |
| Short Ratio |
6.32 |
| Short % of Float |
5.40% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.08 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
353.42M |
| Net Cash / Share |
7.77 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-21.63% |
| ROE |
-44.46% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$28.50*
(80.27% upside)
Low
25.0
Current: $15.81
High
32.5
Target: 28.50
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -37.19 | -13.47 |
| Net Income | -45.63 | -12.77 |
| Shares Outstanding | 4.24 | 3.60 |
| Earnings Per Share | -10.77 | -3.55 |
| Operating Cash Flow | -39.90 | -18.57 |
| Capital Expenditures | -1.19 | -0.03 |
| Free Cash Flow | -41.09 | -18.60 |
| Cash & Equivalents | 159 | 24.86 |
| Net Cash / Debt | 159 | 24.86 |
| Assets | 179 | 33.46 |
| Liabilities | 4.26 | 2.52 |
| Book Value | -56.25 | -12.17 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Passage Bio, Inc. |
| Country |
United States |
| Employees |
20 |
| CEO |
Bruce A. Goldsmith |
Stock Information
| Ticker Symbol |
PASG |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PASG |
| IPO Date |
February 28, 2020 |
Description
Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania. Address: 2 Commerce Square, Philadelphia, PA, United States, 19103